Tag: TYK2
-
Priovant Wins FDA Approval for Lisraya in Dermatomyositis
The FDA approved Lisraya (brepocitinib), the first oral treatment option for adults with dermatomyositis, based on positive Phase 3 VALOR results.
-
How Lisraya Targets Dermatomyositis Through TYK2/JAK1 Inhibition
Lisraya (brepocitinib) inhibits TYK2 and JAK1, reducing STAT-dependent inflammatory signaling involved in skin and muscle inflammation in dermatomyositis.